Literature DB >> 10475363

Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer.

K A McCammon1, P Kolm, B Main, P F Schellhammer.   

Abstract

OBJECTIVES: To determine and compare quality-of-life (QOL) evaluations from patients who received external beam radiation therapy or radical prostatectomy for the treatment of localized prostate cancer, and to compare differences in QOL assessments for urinary and sexual function after radical prostatectomy as reported by patient and physician.
METHODS: Two hundred three patients treated by radical prostatectomy and 257 patients treated by external beam irradiation, all beyond 12-month follow-up after therapy, responded to a QOL questionnaire. The difference in responses with regard to bladder, bowel, and sexual function, overall satisfaction with treatment, and choice of the same treatment were assessed. Satisfaction with and choice of the same treatment were also specifically assessed according to bowel and bladder function and current disease status. The medical records of patients treated by radical prostatectomy were reviewed by an independent data manager to record the physician's assessment of continence and sexual function for comparison with that patient's assessment as noted in the questionnaire.
RESULTS: Problems with urinary continence were more frequent among patients treated by radical prostatectomy; problems with gastrointestinal function were more frequent after irradiation. Sexual dysfunction was similar in both groups, although surgical patients experienced a greater impact on sexual relationships. The physician estimates of urinary continence were more favorable than the patient-reported outcomes. However, the physician estimate of sexual function closely approximated that of the patient. Preservation of sexual function among patients who underwent nerve-sparing surgery was disappointingly low. Only for the response to the question dealing with difficulty in achieving an erection was there a statistically significant benefit for patients receiving nerve-sparing versus non-nerve-sparing procedures. Patient satisfaction with and choice of the same treatment varied according to function and current disease status. Patients who had incontinence or bowel dysfunction or had evidence of recurrent disease were statistically less likely to choose the same treatment again when compared with functional and disease-free counterparts. Because irradiated patients were on average 6 years older than surgical patients, responses were adjusted for age; adjustment for age did not alter results.
CONCLUSIONS: QOL is determined by the treatment received, by the assessment source, and by the patient's function and disease status at the time of assessment. Prospective and longitudinal studies will more accurately quantify immediate and chronic alterations in QOL. Uniformity of evaluation through consolidation of QOL instruments will permit more accurate cross-series and cross-treatment comparisons.

Entities:  

Mesh:

Year:  1999        PMID: 10475363     DOI: 10.1016/s0090-4295(99)00163-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  23 in total

1.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

2.  [Male stress incontinence. A growing therapeutic problem in daily practice].

Authors:  P-M Braun
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

3.  Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria.

Authors:  Anton Ponholzer; Clemens Brössner; Gerhard Struhal; Martin Marszalek; Stephan Madersbacher
Journal:  World J Urol       Date:  2006-04-11       Impact factor: 4.226

4.  Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial.

Authors:  Julia J van Tol-Geerdink; Jan Willem H Leer; Carl J Wijburg; Inge M van Oort; Henk Vergunst; Emile J van Lin; J Alfred Witjes; Peep F M Stalmeier
Journal:  Health Expect       Date:  2015-05-03       Impact factor: 3.377

5.  Advances in the Management of Post-Radical Prostatectomy Erectile Dysfunction: Treatment Strategies When PDE-5 Inhibitors Don't Work.

Authors:  Bruce R Kava
Journal:  Rev Urol       Date:  2005

6.  Therapeutic strategies for localized prostate cancer.

Authors:  J H Lynch; J T Batuello; E D Crawford; L G Gomella; J Kaufman; D P Petrylak; A B Joel
Journal:  Rev Urol       Date:  2001

7.  Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience.

Authors:  F Guedea; M Ferrer; J Pera; F Aguiló; A Boladeras; J F Suárez; O Cunillera; F Ferrer; Y Pardo; E Martínez; M Ventura
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

8.  The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer.

Authors:  G Rodrigues; A Bezjak; D Osoba; P Catton; D Tsuji; D Taylor; P Warde
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

Review 9.  Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment.

Authors:  Cem Akbal; Ilker Tinay; Ferruh Simşek; Levent N Turkeri
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

10.  Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P).

Authors:  Annika Waldmann; Volker Rohde; Karen Bremner; Murray Krahn; Thomas Kuechler; Alexander Katalinic
Journal:  BMC Cancer       Date:  2009-08-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.